Drug
Deucravacitinib clinical trials
Also written BMS-986165 and SOTYKTU.
- studies test it
- 73
- open now
- 11
- in phase 3
- 16
- first study started
- 2016
Keep track of what changes. Save the deucravacitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
73 studies that test it; most in 2019 (16)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 9 |
| 2019 | 16 |
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 2 |
| 2023 | 9 |
| 2024 | 10 |
| 2025 | 6 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 24
- Phase 2
- 20
- Phase 3
- 16
- Phase 4
- 11
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 56 · Other 17
Bristol-Myers Squibb (55) · Centre Hospitalier Universitaire de Nice (2) · Mayo Clinic (2) · University of California, San Francisco (2) · Icahn School of Medicine at Mount Sinai (2) · AbbVie (1) · University of Alabama at Birmingham (1) · Chinese SLE Treatment And Research Group (1)
Often tested with
Tested in the same studies.
Risankizumab (2) · Ustekinumab (2) · Cyclosporine (2) · Methotrexate (2) · Fluvoxamine (1) · BMS-986165-01 (1) · Famotidine (1) · Rabeprazole (1)
Studies
Open first, then newest update. How each study uses deucravacitinib is read from its arms, and is right about nine times in ten.
Testing it · 73
- Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)RecruitingPhase 3Bristol-Myers SquibbNCT07116967Written as Deucravacitinib
- A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisRecruitingPhase 3Bristol-Myers SquibbNCT06869551Written as Deucravacitinib
- A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132RecruitingPhase 4Bristol-Myers SquibbNCT06875960Written as BMS-986165
- Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study CompletersNot yet recruitingPhase 3Bristol-Myers SquibbNCT07791199Written as Deucravacitinib
- A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruitingPhase 3Bristol-Myers SquibbNCT06979453Written as Deucravacitinib
- Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic DiseaseRecruitingPhase 4University of Texas Southwestern Medical CenterNCT07280702Written as Deucravacitinib
- A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruitingPhase 3Bristol-Myers SquibbNCT04772079Written as Deucravacitinib
- Deucravacitinib in the Treatment of Cicatricial AlopeciasRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT07508488Written as Deucravacitinib
- Correction of Psoriatic T Cell Signatures by DeucravacitinibRecruitingPhase 4University of California, San FranciscoNCT05858645Written as deucravacitinib
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Deucravacitinib
- The Efficacy and Safety of Deucravacitinib in Takayasu's ArteritisNot yet recruitingPhase 4Chinese SLE Treatment And Research GroupNCT07013838Written as Deucravacitinib
- A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic DrugsActive, not recruitingPhase 3Bristol-Myers SquibbNCT04908202Written as Deucravacitinib
- A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory GenodermatosesCompletedPhase 2Centre Hospitalier Universitaire de NiceNCT06136403Written as deucravacitinib
- A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor TreatmentActive, not recruitingPhase 3Bristol-Myers SquibbNCT04908189Written as Deucravacitinib
- Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With PsoriasisCompletedPhase 3Bristol-Myers SquibbNCT04036435Written as BMS-986165
- Deucravacitinib (BMS-986165) for Pityriasis Rubra PilarisCompletedPhase 2Mayo ClinicNCT06444399Written as Deucravacitinib
- A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community SettingCompletedPhase 4Bristol-Myers SquibbNCT05701995Written as Deucravacitinib
- Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).TerminatedPhase 2Beth Israel Deaconess Medical CenterNCT05997277Written as Deucravacitinib
- Vitiligo Treatment by Targeting TYK2 Mediated ResponsesActive, not recruitingPhase 2Centre Hospitalier Universitaire de NiceNCT06327321Written as Deucravacitinib
- A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital PsoriasisTerminatedPhase 4Bristol-Myers SquibbNCT06042920Written as Deucravacitinib
See all 73 studies that test deucravacitinib →
Given in every arm · 7 — deucravacitinib is usual care beside what is tested
- A Study of BMS986365 in Combination With Degarelix in People With Prostate CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07335796Written as BMS-986165
- A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy AdultsCompletedPhase 1Bristol-Myers SquibbNCT06851871Written as Deucravacitinib
- Combination of Sotyktu and Enstilar for Plaque PsoriasisCompletedPhase 4Psoriasis Treatment Center of Central New JerseyNCT06329258Written as Deucravacitinib
- A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT04949269Written as Deucravacitinib
- The Effects Diflunisal on the Levels of BMS-986165 in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT04113668Written as BMS-986165
- A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy VolunteersCompletedPhase 1Bristol-Myers SquibbNCT04209699Written as BMS-986165
- Safety Study of BMS-986165 in Healthy Subjects and to Treat PsoriasisCompletedPhase 1Bristol-Myers SquibbNCT02534636Written as BMS-986165
As the comparator · 5 — what is tested is compared with deucravacitinib
- A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque PsoriasisRecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07724366Written as Deucravacitinib tablets 6 mg
- A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque PsoriasisRecruitingPhase 3InventisBio Co., LtdNCT07326813Written as BMS-986165 Tablet
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)Active, not recruitingPhase 3Janssen Research & Development, LLCNCT06220604Written as Deucravacitinib
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisActive, not recruitingPhase 3Janssen Research & Development, LLCNCT06143878Written as Deucravacitinib
- A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque PsoriasisCompletedPhase 3TakedaNCT06973291Written as Deucravacitinib
Codes
What other systems call deucravacitinib · ClinicalTrials.gg INT000999
- MeSH (NLM) C000628674deucravacitinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) N0A21N6RAUDEUCRAVACITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2612087One source FDA
- Wikidata Q113940477deucravacitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174730DeucravacitinibOne source FDA
- DrugBank DB16650One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000628674 | deucravacitinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | N0A21N6RAU | DEUCRAVACITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2612087 | — | One source FDA |
| Wikidata | Q113940477 | deucravacitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174730 | Deucravacitinib | One source FDA |
| DrugBank | DB16650 | — | One source Wikidata |
Also registered as deucravacitinib hydrochloride (UNII 95C5558CF4).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.